Immunai
@Immunaitech
Followers
1K
Following
49
Media
32
Statuses
131
Decoding the Immune System to Improve Health
Joined May 2020
Big news: @Immunai has won the @FierceBiotech Life Sciences Award for AI Innovation. Fierce showcased our AMICA™ platform and its success in forecasting patient response - a major step toward more precise development.
fiercebiotech.com
Fierce Innovation Awards2025 Life Sciences EditionThe life sciences industry has expanded far beyond the wet lab. Developing life-changing medicines, medical devices, and diagnostics requires a...
0
0
2
New in Blood Advances: our Immunai team, with Mount Sinai & Janssen R&D, identified immune features predicting long-term response to CAR T therapy in multiple myeloma. 🔗 https://t.co/CvQ37xEoUR
#Immunai #CART #MultipleMyeloma #Immunotherapy #PrecisionMedicine
ashpublications.org
Junia Vieira dos Santos, David T Melnekoff, Adolfo Aleman, Tarek H Mouhieddine, Rocio Montes de Oca, Feng Wang, Sridevi Rajeeve, Sherry Bhalla, Oliver Van
0
0
2
Immunai has been named a finalist in the @FierceHealth : Life Sciences Edition 2025 (AI Innovation category)! Our AMICA™, CT-OS™, and PE-OS™ platforms are driving a new wave of immune intelligence, where AI helps predict, not just treat, disease. https://t.co/nsbnEIJvD4
0
0
1
Proud to expand our work with @AstraZeneca into inflammatory bowel disease. IBD affects 10M+ people worldwide, with many still cycling through treatments. With Immunai’s IDE™ and AMICA™, we’re uncovering and exploring new immune targets. @FierceBiotech: https://t.co/ISS72FQdcL
fiercebiotech.com
AstraZeneca has returned to its longtime artificial intelligence partner Immunai with a new deal worth up to $85 million to advance a suitable target for a new inflammatory bowel disease (IBD) ther |...
0
3
6
Research in immunity can’t wait for funding. We launched the Grand Collaboration Initiative to give researchers free access to immune mapping tools: accelerating discoveries in cancer, autoimmunity, and beyond. More in @PharmaVoice
pharmavoice.com
An AI revolution is taking place, and leaders from tech to Big Pharma are forecasting what drugmakers of the future will look like.
0
0
1
Research in immunity can’t wait for funding. Immunai’s Grand Collaboration Initiative is giving researchers free access to our immune mapping tools to speed discoveries in cancer, autoimmunity, and more.
druganddeviceworld.com
Immunai co-founder and CEO, Noam Solomon, discusses the Grand Collaboration Initiative and the future of immune profiling.
0
0
0
Immunai’s Grand Collaboration is now open! Single-cell immune sequencing for academic researchers to advance immune system understanding. ✔️ High-resolution, multi-omic data 🧬 Enrichment of the AMICA atlas 🗓️ Applications due by Oct 1, 2025 #scRNAseq #Immunai #AcademicResearch
0
1
1
Excited to share our work at #BiomedIsrael! Elisha Nathan presents how Immunai de-risks immunotherapy development using AI + single-cell multi-omics. Powered by AMICA, the world’s largest clinical immune db. #Immunai #DrugDevelopment #Oncology #Autoimmune
0
0
0
Our CEO @NoamSolomon1 just joined a very impressive club: @INVIVOnow’s 2025 Rising Leaders💥 This list features 30 people shaking up biotech, medtech, and global health. Proud moment for the @Immunaitech team.
insights.citeline.com
The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health...
0
0
0
At #DDW2025, Immunai & @AstraZeneca share new IBD research using single-cell data + functional genomics. Deleting one target reduced TNFα/IFNγ in macrophages - showing real therapeutic potential. 📷 Read more: https://t.co/UOiCPIUfRW #IBD #Immunology #DrugDiscovery #AIinBiotech
eposters.ddw.org
DDW ePoster Library; Nayar S. May 4 2025; 4156114;
0
0
1
We’re teaming up with @parkerici to build one of the largest real-world single-cell datasets. Integrated into AMICA™, this will power immune insights across cancers, accelerating discovery + reducing trial risk https://t.co/EQiUt0b4sN
genengnews.com
Immunai will generate a publicly accessible multi-omic dataset for a Parker Institute cohort of over 1,000 cancer patients.
0
0
0
🧬 Heading to #AACR25? Meet Immunai CEO Noam Solomon, CTO Adeeb Rahman, & VP BD Evan Zisholtz 📌 See our April 30 poster on predicting aPD1 response using a human ex vivo tumor model + multiomic data. #Immunotherapy #CancerResearch #Multiomics
0
0
0
After leading R&D at Pfizer, Dr. Mikael Dolsten is entering a new chapter. He’s joining Immunai’s board to help advance AI-powered drug development. Read about his move and outlook on the future of biopharma via @PharmaVoice:
pharmavoice.com
Dr. Mikael Dolsten, Pfizer’s former chief scientific officer, is embarking on a journey of curiosity and interconnectedness in his post-Big Pharma career.
0
0
1
Dr. Mikael Dolsten, a leader behind 35+ approved therapies, is bringing his expertise to Immunai’s Board. His experience in R&D and immunology will help us deepen AI’s role in drug discovery, bringing new treatments to patients faster. https://t.co/8LtLUccNCq
0
0
2
🧬 Inside Immunai kicks off 2025 with Eva Macuchova, our Scientific Team Lead! At Immunai, she’s helped standardize data & fuel AI-powered discoveries in cancer & inflammatory research. Crime novel lover, foodie, & data expert—join her team! https://t.co/jPsvUzXH1w
0
0
0
Immunai has been named Startup of the Week via @theinnovator⭐️ Read how Immunai is bridging the gap between computer science and life sciences to combat Eroom’s Law—the rising costs of drug development. https://t.co/hozNm0FLJh
theinnovator.news
The Innovator presents digital transformation experts, insights on how startups are changing business, and exploring where business connects with tech.
0
0
4
Our CEO @NoamSolomon1 is headed to Davos to represent Immunai as part of the @WEF Unicorn Program with other high-growth companies shaping the future of their industries. Are you attending?
1
0
1
AI has massive potential in immunotherapies—so why is drug development still lagging? In @hitconsultant, our CEO, @NoamSolomon1 unpacks data gaps, immune system mapping, and how AI can transform the process. Read:
hitconsultant.net
To advance the potential of AI in drug development, At Immunai, we are building an AI model of the immune system that can address the...
0
1
1
What drives progress in cancer treatment? At Immunai, it starts with the team above all. Healthy debate and shared commitment power our breakthroughs in immunology and beyond. Read more from @MichaBreakstone and @Inc:
inc.com
This AI company's values help drive its booming biotech business.
0
0
0
95% of drugs fail before reaching patients. Our CEO @NoamSolomon1 joined @MaayanJaffe on @ILTVNews’s Lights of Hope panel to discuss how AI and our immune cell atlas are improving clinical trial efficiency and driving better outcomes.
ynetnews.com
Noam Solomon: 'We have so many startups and IT companies succeeding, and we can tap into this, source amazing talent'
0
0
1